Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.

“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.

Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.